A carregar...
A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
PURPOSE: Complement may play a role in the clinical response to rituximab and other monoclonal antibody–based therapies of cancer. The purpose of this study was to explore the relationship between the C1qA([276]) polymorphism and the clinical response to rituximab in patients with follicular lymphom...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2907116/ https://ncbi.nlm.nih.gov/pubmed/18927313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0745 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|